Medtronic announced Friday that FDA has approved the the first MR-conditional cardiac resynchronization therapy defibrillators (CRT-Ds) for the treatment of heart failure in the U.S.
The Medtronic Amplia MRI Quad CRT-D SureScan and Compia MRI Quad CRT-D SureScan systems are approved for MRI scans on any part of the body without any kind of positioning restrictions. The products will be launched commercially soon.
|The MR-Conditional CRT-D device from Medtronic|
“What's clear from the data and my own personal experience is that a large majority of CRT-D patients will likely need an MRI at some point. Now that CRT-D MRI devices are approved, patients can receive an MRI in a straightforward manner,” said Dr. J. Rod Gimbel, Case Western Reserve University, in a Medtronic news release. “This is a significant development for heart failure patients with CRT-D therapy."
Medtronic believes as many as 40% of CRT patients will require an MRI within four years after receiving a device.
While the approval of the two Amplia and Compia devices is the first approval of a CRT-D device that is considered compatible with MRI scans in the U.S., European patients have accessed this technology for a few years now.
In 2012, Biotronik received CE Mark for the first CRT-D device that was MR-Conditional, according to Venice Arrhythmias. About 60 million MRI scans are performed globally every year, according to a 2008 paper.
|Read about the Biggest Medtech M&A Deals of 2015. And to understand industry trends, attend the MD&M West Conference, Feb. 9-11, at the Anaheim Convention Center, Anaheim, California.|